Table 1.
General characteristics of the subjects according to the hyperglycemic patterns.
| Persistent Normoglycemia | Baseline Hyperglycemia | 24-h Hyperglycemia | Persistent Hyperglycemia | p | |
|---|---|---|---|---|---|
| (n = 116) | (n = 36) | (n = 17) | (n = 31) | ||
| Demographic data | |||||
| Age, years | 73 (67–80) | 75 (68.2–82) | 75 (66.5–78.5) | 72 (69–79) | 0.7 |
| Males, n (%) | 61 (52.6) | 14 (38.9) | 7 (41.2) | 19 (61.3) | 0.2 |
| Vascular risk factors | |||||
| Previous transient ischemic attack/stroke, n (%) | 11 (9.5) | 2 (5.6) | 3 (17.6) | 3 (9.7) | 0.6 |
| Cardiovascular disease, n (%) | 22 (19.0) | 7 (19.4) | 3 (17.6) | 5 (16.1) | 0.9 |
| Atrial fibrillation, n (%) | 31 (26.7) | 13 (36.1) | 3 (17.6) | 6 (19.4) | 0.4 |
| Hypertension, n (%) | 83 (72.2) | 26 (72.2) | 13 (76.5) | 26 (83.9) | 0.6 |
| Diabetes mellitus, n (%) | 7 (6.0) | 6 (16.7) | 3 (17.6) | 13 (41.9) | 0.001 |
| Hypercholesterolemia, n (%) | 25 (21.6) | 9 (25.0) | 1 (5.9) | 13 (41.9) | 0.03 |
| Current smoking, n (%) | 21 (18.1) | 7 (19.4) | 5 (29.4) | 9 (29.0) | 0.5 |
| Laboratory findings | |||||
| HbA1c values, % | 5.7 (5.4–6.0) | 6.0 (5.7–6.4) | 6.0 (5.9–6.4) | 6.4 (5.8–7.1) | 0.001 |
| Total cholesterol, mg/dL | 164 (145–195.5) | 171 (145–194) | 166 (122.2–206.7) | 154 (135.2–170) | 0.5 |
| HDL cholesterol, mg/dL | 51 (41–62) | 50 (41–63.2) | 47.5 (30.75–62.2) | 46 (39–59) | 0.7 |
| LDL cholesterol, mg/dL | 95 (77–121.2) | 95.5 (80–121.2) | 94.5 (67.2–124.5) | 87 (68–101) | 0.8 |
| Triglycerides, mg/dL | 92 (70–130.5) | 85 (63–123) | 73.5 (56.7–139) | 95 (67.5–143.5) | 0.4 |
| Blood pressure | |||||
| Systolic blood pressure, mmHg | 151 (130–170) | 155 (143–163) | 154 (145–168) | 155 (138–180) | 0.7 |
| Antithrombotic treatment at admission | |||||
| Antiplatelets, n (%) | 28 (24.1) | 13 (36.1) | 5 (29.4) | 14 (45.2) | 0.1 |
| Anticoagulants, n (%) | 16 (13.8) | 6 (16.7) | 2 (11.8) | 3 (9.7) | 0.9 |
| Stroke subtypes based on TOAST classification | 0.6 | ||||
| Large arterial atherosclerosis, n (%) | 19 (16.4) | 6 (16.7) | 2 (11.8) | 6 (19.4) | |
| Cardioembolism, n (%) | 60 (51.7) | 16 (44.4) | 10 (58.8) | 14 (45.2) | |
| Other determined etiology, n (%) | 6 (5.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Undetermined etiology, n (%) | 31 (26.7) | 14 (38.9) | 5 (29.4) | 11 (35.5) | |
| Baseline clinical characteristics | |||||
| Alteplase use before MT, n (%) | 66 (56.9) | 22 (61.1) | 8 (47.1) | 20 (64.5) | 0.7 |
| NIHSS score at admission | 16.5 (13–20) | 19 (15.2–22) | 17 (14.5–19.5) | 18 (15–22) | 0.2 |
| NIHSS score at discharge | 3 (1–8.7) | 9 (2–16.7) | 7.5 (1.7–17.7) | 12 (2.5–16.5) | 0.04 |
| Pre-stroke mRS 0–2, n (%) | 103 (88.8) | 34 (94.4) | 17 (100) | 28 (90.3) | 0.4 |
HbA1c: glycated hemoglobin; MT: mechanical thrombectomy; NIHSS: National Institute of Health Stroke Scale; mRS: modified Rankin Scale.